JCI Insight (Oct 2021)

Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome

  • Annie Arguello,
  • René Meisner,
  • Elliot R. Thomsen,
  • Hoang N. Nguyen,
  • Ritesh Ravi,
  • Jeffrey Simms,
  • Iris Lo,
  • Jessica Speckart,
  • Julia Holtzman,
  • Thomas M. Gill,
  • Darren Chan,
  • Yuhsiang Cheng,
  • Chi-Lu Chiu,
  • Jason C. Dugas,
  • Meng Fang,
  • Isabel A. Lopez,
  • Hilda Solanoy,
  • Buyankhishig Tsogtbaatar,
  • Yuda Zhu,
  • Akhil Bhalla,
  • Kirk R. Henne,
  • Anastasia G. Henry,
  • Anthony Delucchi,
  • Simona Costanzo,
  • Jeffrey M. Harris,
  • Dolores Diaz,
  • Kimberly Scearce-Levie,
  • Pascal E. Sanchez

Journal volume & issue
Vol. 6, no. 19

Abstract

Read online

Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder caused by deficiency of the iduronate-2-sulfatase (IDS) enzyme, resulting in cellular accumulation of glycosaminoglycans (GAGs) throughout the body. Treatment of MPS II remains a considerable challenge as current enzyme replacement therapies do not adequately control many aspects of the disease, including skeletal and neurological manifestations. We developed an IDS transport vehicle (ETV:IDS) that is engineered to bind to the transferrin receptor; this design facilitates receptor-mediated transcytosis of IDS across the blood-brain barrier and improves its distribution into the brain while maintaining distribution to peripheral tissues. Here we show that chronic systemic administration of ETV:IDS in a mouse model of MPS II reduced levels of peripheral and central nervous system GAGs, microgliosis, and neurofilament light chain, a biomarker of neuronal injury. Additionally, ETV:IDS rescued auricular and skeletal abnormalities when introduced in adult MPS II mice. These effects were accompanied by improvements in several neurobehavioral domains, including motor skills, sensorimotor gating, and learning and memory. Together, these results highlight the therapeutic potential of ETV:IDS for treating peripheral and central abnormalities in MPS II. DNL310, an investigational ETV:IDS molecule, is currently in clinical trials as a potential treatment for patients with MPS II.

Keywords